MER4 endogenous retrovirus correlated with better efficacy of anti-PD1/PD-L1 therapy in non-small cell lung cancer.
Fiche publication
Date publication
mars 2022
Journal
Journal for immunotherapy of cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BOIDOT Romain, Pr GHIRINGHELLI François, Mme TRUNTZER Caroline, Dr FAVIER Laure
Tous les auteurs :
Lecuelle J, Favier L, Fraisse C, Lagrange A, Kaderbhai C, Boidot R, Chevrier S, Joubert P, Routy B, Truntzer C, Ghiringhelli F
Lien Pubmed
Résumé
Endogenous retroviruses (ERVs) are highly expressed in various cancer types and are associated with increased innate immune response and better efficacy of antiprogrammed death-1/ligand-1 (anti-PD1/PD-L1)-directed immune checkpoint inhibitors (ICI) in preclinical models. However, their role in human non-small cell lung cancer (NSCLC) remains unknown.
Mots clés
biomarkers, tumor, biostatistics, immunotherapy
Référence
J Immunother Cancer. 2022 Mar;10(3):